MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 2, 2014, Pages 917-923

  Zhu, Zhe ^a,b   Wang, Cun Ping ^b   Zhang, Yin Feng ^c   Nie, Lin ^a  

^a SHANDONG UNIVERSITY   (China)

^b Department of Urology   (China)

^c Cardiovascular Medicine   (China)

Author keywords

Chemoresistance; Chondrosarcoma; Cisplatin; MicroRNA; MTOR

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; MESSENGER RNA; MICRORNA; MIRN100 MICRORNA, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; BONE TUMOR; CARTILAGE CELL; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CHONDROSARCOMA; CYTOLOGY; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; CHONDROCYTES; CHONDROSARCOMA; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TOR SERINE-THREONINE KINASES;

EID: 84894680007     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.2.917     Document Type: Article

References (34)

1. Ameres SL, Zamore PD (2013). Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol, 14, 475-88.
2. Barr MP, Gray SG, Hoffmann AC, et al (2013). Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One, 8, e54193.
3. Caron E, Ghosh S, Matsuoka Y, et al (2010). A comprehensive map of the mTOR signaling network. Mol Syst Biol, 21, 453.
4. Chen P, Zhao X, Ma L (2013). Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem, 383, 49-58.
5. Croce CM (2009). Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet, 10, 704-14.
6. Fiorenza F, Abudu A, Grimer RJ, et al (2002). Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br, 84, 93-9.
7. Galluzzi L, Senovilla L, Vitale I, et al (2012). Molecular mechanisms of cisplatin resistance. Oncogene, 31, 1869-83.
8. Gelderblom H, Hogendoorn PCW, Dijkstra SD, et al (2008). The clinical approach towards chondrosarcoma. Oncologist, 13, 320-9.
9. Germani A, Matrone A, Grossi V, et al (2013). Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38α modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A. Cancer Lett, 344, 110-8.
10. Henson BJ, Bhattacharjee S, O'Dee DM, Feingold E, Gollin SM (2009). Decreased expression of miR-100 and miR-100 in oral cancer cells contributes to malignancy. Genes Chromosomes Cancer, 48, 569-82.
11. Juliachs M, Munoz C, Moutinho C, et al (2013). The PDGFRβ-AKT Pathway Contributes To CDDP-Acquired Resistance In Testicular Germ Cell Tumors. Clin Cancer Res, [Epub ahead of print].
12. Laplante M, Sabatini DM (2012). mTOR signaling in growth control and disease. Cell, 13, 274-93.
13. Li H, Zhang X, Song X (2012). PDCD5 promotes cisplatin-induced apoptosis of glioma cells via activating mitochondrial apoptotic pathway. Cancer Biol Ther, 13, 822-30.
14. Lin C, McGough R, Aswad B, Block JA, Terek R (2004). Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes. J Orthop Res, 22, 1175-81.
15. Liu J, Lu KH, Liu ZL, et al (2012). MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1. BMC Cancer, 14, 519.
16. Ma J, Dong C, Ji C, et al (2010). MicroRNA and drug resistance. Cancer Gene Ther. 17, 523-31.
17. Mabuchi S, Altomare DA, Cheung M, et al (2007). RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res, 13, 4261-70.
18. Mir R, Stanzani E, Martinez-Soler F, Villanueva A, et al (2013). YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression. Gynecol Oncol, 132, 211-20.
19. Nagaraja AK, Creighton CJ, Yu Z, et al (2010). A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol, 24, 447-63.
20. Negoro K, Yamano Y, Fushimi K, et al (2007). Establishment and characterization of a cisplatin-resistant cell line, KB-R, derived from oral carcinoma cell line, KB. Int J Oncol, 30, 1325-32.
21. Onishi AC, Hincker AM, Lee FY (2011). Surmounting chemotherapy and radioresistance in chondrosarcoma: molecular mechanisms and therapeutic targets. Sarcoma, 2011, 381564.
22. Parsch D, Brassat U, Brümmendorf TH, Fellenberg J (2008). Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines. Cancer Invest, 26, 590-6.
23. Pendleton KP, Grandis JR (2013). Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck. Clin Med Insights Ther, 2013, S10409.
24. Schrage YM, Lam S, Jochemsen AG, et al (2009). Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro. J Cell Mol Med, 13, 2843-52.
25. Shin DH, Choi YJ, Park JW (2013). SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin. Cancer Res, [Epub ahead of print].
26. Steelman LS, Navolanic P, Chappell WH, et al (2011). Involvement of Akt and mTOR in chemotherapeutic-and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle, 10, 3003-15.
27. Sternberg CN, Skoneczna IA, Castellano D, et al (2013). Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB). Oncology, 85, 208-15.
28. Van Oosterwijk JG, Anninga JK, Gelderblom H, Cleton-Jansen AM, Bovée JV (2013). Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma. Hematol Oncol Clin North Am, 27, 1021-48.
29. Wang J, Zhou JY, Zhang L, Wu GS (2009). Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. Cell Cycle, 8, 3191-8.
30. Xu C, Zeng Q, Xu W, et al (2013). miRNA-100 inhibits human bladder urothelial carcinogenesis by directly targeting mTOR. Mol Cancer Ther, 12, 207-19.
31. Yardley DA (2013). Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions. Breast Cancer, 7, 7-22.
32. Yoshitaka T, Kawai A, Miyaki S, et al (2013). Analysis of microRNAs expressions in chondrosarcoma. J Orthop Res, 31, 1992-8.
33. Zhang YX, van Oosterwijk JG, Sicinska E, et al (2013). Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy. Clin Cancer Res, 19, 3796-807.
34. Zheng T, Wang J, Chen X, Liu L (2010). Role of microRNA in anticancer drug resistance. Int J Cancer, 126, 2-10.